Target intelligence / Profile preview

Zinc metallopeptidase STE24 (ZMPSTE24)

Target
ZMPSTE24
Molecular classification
Enzyme, Integral membrane protein, Zinc metalloprotease, Peptidase M48A family
01

Overview

Zinc metallopeptidase STE24 (ZMPSTE24) is an integral membrane zinc-dependent metalloprotease critical for the post-translational maturation of lamin A, a major structural component of the nuclear envelope. ZMPSTE24 cleaves farnesylated prelamin A at defined sites on the nuclear envelope and endoplasmic reticulum, enabling the generation of mature lamin A, which is essential for proper nuclear architecture and gene regulation[1][3][6]. The protein also acts in ER protein quality control by removing aberrant, misfolded secretory protein fragments from translocons and serves as an innate antiviral restriction factor, helping block entry and fusion of a wide range of enveloped viruses, including coronaviruses, influenza, and more[3][5]. Disease-associated mutations or drug-induced inhibition of ZMPSTE24 lead to accumulation of toxic prelamin A, precipitating progeroid syndromes (e.g., Hutchinson-Gilford progeria syndrome), lipodystrophy, restrictive dermopathy, and increased susceptibility to viral infections[1][3][5]. The unique structure of ZMPSTE24 features a seven-transmembrane barrel-like architecture with a catalytic HEXXH motif and a central chamber where substrate cleavage occurs[2][4].

Other names
CAAX prenyl protease 1 homologFACE1STE24FACE-1Ste24pFarnesylated proteins-converting enzyme 1Prenyl protein-specific endoprotease 1Zinc metalloproteinase Ste24 homologHGPSPRO1Restrictive dermopathy 1 proteinRSDM1
02

Mechanism of action

Competitive inhibition of enzymatic activity by HIV protease inhibitors

03

Biological functions

Proteolytic maturation of prelamin APost-translational processing of farnesylated proteinsMaintenance of nuclear envelope structureClearance of clogged ER translocons (ER protein quality control)Antiviral activity (restriction factor for enveloped viruses)
04

Disease associations

Premature aging diseases (progeroid syndromes, e.g., Hutchinson-Gilford progeria syndrome)Mandibuloacral dysplasiaRestrictive dermopathyLipodystrophyAntiviral defense (against influenza, Zika, Ebola, SARS-CoV-2, and more)
05

Safety considerations

Inhibition can cause accumulation of toxic farnesylated prelamin A, leading to premature aging syndromes and tissue fragilityOff-target inhibition by certain drugs (e.g., HIV protease inhibitors) can promote progeroid phenotypes
06

Interacting drugs

HIV protease inhibitors (e.g., lopinavir)
07

Biomarkers

Prelamin A accumulation (for diagnosing ZMPSTE24-related disorders)Lamin A levels (for efficacy monitoring)

Beyond the preview

Go deeper on Zinc metallopeptidase STE24 (ZMPSTE24).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinc metallopeptidase STE24 (ZMPSTE24).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call